Asensus Surgical Financial Statements ()
|
|
|
|
Report date
|
|
|
11.03.2021 |
28.02.2022 |
30.06.2022 |
02.03.2023 |
29.04.2024 |
|
13.08.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
3.18 |
8.23 |
|
7.09 |
8.58 |
|
9.85 |
|
Operating Income, bln rub |
|
|
-60.4 |
-64.6 |
|
-75.7 |
-79.5 |
|
-77.5 |
|
EBITDA, bln rub |
? |
|
-47.1 |
-47.8 |
|
-64.3 |
-74.4 |
|
-75.1 |
|
Net profit, bln rub |
? |
|
-59.3 |
-62.5 |
|
-75.6 |
-78.4 |
|
-83.8 |
|
|
OCF, bln rub |
? |
|
-46.7 |
-40.7 |
|
-58.9 |
-63.6 |
|
-56.7 |
|
CAPEX, bln rub |
? |
|
0.003 |
1.37 |
|
1.28 |
0.561 |
|
0.506 |
|
FCF, bln rub |
? |
|
-46.7 |
-42.0 |
|
-60.2 |
-64.2 |
|
-57.2 |
|
Dividend payout, bln rub
|
|
|
0.412 |
0.000 |
|
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
|
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
54.6 |
63.3 |
|
71.6 |
73.1 |
|
67.8 |
|
Cost of production, bln rub |
|
|
5.17 |
11.1 |
|
10.9 |
13.2 |
|
13.2 |
|
R&D, bln rub |
|
|
16.6 |
19.3 |
|
28.9 |
37.0 |
|
33.6 |
|
Interest expenses, bln rub |
|
|
0.019 |
0.370 |
|
0.410 |
0.000 |
|
0.321 |
|
|
Assets, bln rub |
|
|
78.3 |
186.5 |
147.4 |
116.1 |
60.5 |
|
38.5 |
|
Net Assets, bln rub |
? |
|
61.6 |
169.2 |
131.4 |
99.6 |
33.4 |
|
-11.3 |
|
Debt, bln rub |
|
|
4.13 |
5.69 |
5.19 |
5.54 |
5.68 |
|
21.5 |
|
Cash, bln rub |
|
|
16.4 |
98.4 |
94.2 |
70.5 |
21.1 |
|
7.78 |
|
Net debt, bln rub |
|
|
-12.2 |
-92.7 |
-89.0 |
-65.0 |
-15.4 |
|
13.7 |
|
|
Ordinary share price, rub |
|
|
0.630 |
1.11 |
0.398 |
0.347 |
0.319 |
|
0.333 |
|
Number of ordinary shares, mln |
|
|
70.8 |
227.0 |
|
236.5 |
249.7 |
|
272.3 |
|
|
Market cap, bln rub |
|
|
45 |
252 |
0 |
82 |
80 |
|
91 |
|
EV, bln rub |
? |
|
32 |
159 |
-89 |
17 |
64 |
|
104 |
|
Book value, bln rub |
|
|
39 |
159 |
131 |
98 |
32 |
|
-12 |
|
|
EPS, rub |
? |
|
-0.84 |
-0.28 |
|
-0.32 |
-0.31 |
|
-0.31 |
|
FCF/share, rub |
|
|
-0.66 |
-0.19 |
|
-0.25 |
-0.26 |
|
-0.21 |
|
BV/share, rub |
|
|
0.56 |
0.70 |
|
0.41 |
0.13 |
|
-0.05 |
|
|
EBITDA margin, % |
? |
|
-1 484% |
-580.1% |
|
-907.1% |
-867.4% |
|
-762.1% |
|
Net margin, % |
? |
|
-1 868% |
-758.8% |
|
-1 066% |
-914.5% |
|
-850.8% |
|
FCF yield, % |
? |
|
-104.6% |
-16.7% |
0.00% |
-73.4% |
-80.6% |
|
-63.0% |
|
ROE, % |
? |
|
-96.3% |
-36.9% |
0.00% |
-75.8% |
-234.7% |
|
739.8% |
|
ROA, % |
? |
|
-75.8% |
-33.5% |
0.00% |
-65.1% |
-129.6% |
|
-217.6% |
|
|
P/E |
? |
|
-0.75 |
-4.03 |
|
-1.09 |
-1.02 |
|
-1.08 |
|
P/FCF |
|
|
-0.96 |
-5.99 |
|
-1.36 |
-1.24 |
|
-1.59 |
|
P/S |
? |
|
14.1 |
30.6 |
|
11.6 |
9.28 |
|
9.21 |
|
P/BV |
? |
|
1.14 |
1.58 |
0.00 |
0.84 |
2.47 |
|
-7.35 |
|
EV/EBITDA |
? |
|
-0.69 |
-3.33 |
|
-0.27 |
-0.86 |
|
-1.39 |
|
Debt/EBITDA |
|
|
0.26 |
1.94 |
|
1.01 |
0.21 |
|
-0.18 |
|
|
R&D/CAPEX, % |
|
|
554 033% |
1 414% |
|
2 263% |
6 599% |
|
6 645% |
|
|
CAPEX/Revenue, % |
|
|
0.09% |
16.6% |
|
18.0% |
6.54% |
|
5.14% |
|
| Asensus Surgical shareholders |
